Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in patients with peripheral arterial occlusive disease (PAOD) and intermittent claudication.

Trial Profile

A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in patients with peripheral arterial occlusive disease (PAOD) and intermittent claudication.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitroglycerin (Primary)
  • Indications Intermittent claudication; Peripheral arterial occlusive disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pohl-Boskamp
  • Most Recent Events

    • 01 Mar 2021 Primary endpoint (One primary endpoint is defined as the increase in “walking distance” measured as initial claudication distance (ICD) at Visit 7 (end of treatment period) compared to baseline. A further primary endpoint is the walking distance by absolute claudication distance (ACD) at Visit 7 (end of treatment period) compared to baseline), has not been met according to Results published in the European Journal of Vascular and En
    • 01 Mar 2021 Results published in the European Journal of Vascular and Endovascular Surgery
    • 04 Jan 2019 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top